Global X MANAGEMENT CO LLC raised its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 12.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,999 shares of the pharmaceutical company’s stock after acquiring an additional 558 shares during the quarter. Global X MANAGEMENT CO LLC’s holdings in Vertex Pharmaceuticals were worth $760,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in VRTX. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in shares of Vertex Pharmaceuticals by 0.4% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 18,504 shares of the pharmaceutical company’s stock valued at $2,385,000 after buying an additional 75 shares in the last quarter. Buckingham Asset Management LLC increased its position in shares of Vertex Pharmaceuticals by 3.6% in the second quarter. Buckingham Asset Management LLC now owns 2,265 shares of the pharmaceutical company’s stock valued at $292,000 after buying an additional 79 shares in the last quarter. Grandfield & Dodd LLC increased its position in shares of Vertex Pharmaceuticals by 1.6% in the second quarter. Grandfield & Dodd LLC now owns 5,805 shares of the pharmaceutical company’s stock valued at $748,000 after buying an additional 90 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its position in shares of Vertex Pharmaceuticals by 1.6% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 6,383 shares of the pharmaceutical company’s stock valued at $823,000 after buying an additional 101 shares in the last quarter. Finally, Teacher Retirement System of Texas increased its position in shares of Vertex Pharmaceuticals by 4.4% in the second quarter. Teacher Retirement System of Texas now owns 2,661 shares of the pharmaceutical company’s stock valued at $343,000 after buying an additional 113 shares in the last quarter. 92.79% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at $147.94 on Friday. The company has a current ratio of 3.28, a quick ratio of 3.14 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $37,596.53, a price-to-earnings ratio of 247.77, a price-to-earnings-growth ratio of 3.78 and a beta of 1.63. Vertex Pharmaceuticals Incorporated has a 1 year low of $71.46 and a 1 year high of $167.85.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.49. The company had revenue of $578.20 million during the quarter, compared to the consensus estimate of $522.07 million. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. Vertex Pharmaceuticals’s revenue was up 39.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.16 earnings per share. sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 0.72 EPS for the current fiscal year.

A number of analysts have recently commented on the company. Oppenheimer Holdings, Inc. boosted their price objective on Vertex Pharmaceuticals from $150.00 to $175.00 and gave the company an “outperform” rating in a research report on Thursday, July 27th. BMO Capital Markets restated a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Wednesday, September 27th. Robert W. Baird reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Friday, October 27th. Needham & Company LLC reiterated a “buy” rating and set a $195.00 price target on shares of Vertex Pharmaceuticals in a research report on Sunday, September 17th. Finally, Argus boosted their price target on Vertex Pharmaceuticals from $71.46 to $175.00 and gave the stock a “buy” rating in a research report on Tuesday, August 1st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-three have assigned a buy rating to the company’s stock. Vertex Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $173.15.

In other Vertex Pharmaceuticals news, COO Ian F. Smith sold 2,155 shares of the business’s stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $150.00, for a total transaction of $323,250.00. Following the completion of the sale, the chief operating officer now owns 43,043 shares of the company’s stock, valued at $6,456,450. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Jeffrey Chodakewitz sold 1,718 shares of the business’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $155.19, for a total value of $266,616.42. Following the sale, the chief marketing officer now directly owns 116,142 shares of the company’s stock, valued at approximately $18,024,076.98. The disclosure for this sale can be found here. In the last ninety days, insiders sold 220,094 shares of company stock valued at $32,074,719. Company insiders own 1.80% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Global X MANAGEMENT CO LLC Has $760,000 Holdings in Vertex Pharmaceuticals Incorporated (VRTX)” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://theolympiareport.com/2017/11/17/global-x-management-co-llc-has-760000-holdings-in-vertex-pharmaceuticals-incorporated-vrtx.html.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.